Updated analysis of a phase 3 trial in 590 female patients with untreated HER2-positive metastatic breast cancer: adding pyrotinib to trastuzumab and docetaxel kept median PFS longer (22.1 vs 10.5 months; HR 0.44) and improved overall survival (HR 0.64) vs placebo.
RCTn = 590
Ma et al. Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial